I guess the time frame is in line, it's a long ways out especially since we haven't started a trial yet ..below are some links on your article and some others may not have seen...thanks
ISCO's human parthenogenetic stem cells have the potential to treat human disease yet possess key medical and ethical advantages over other kinds of stem cell products. They can be matched to common immune types and thus reduce the chance of transplant rejection among large segments of the population. Because they are created from unfertilized human eggs, they do not require the destruction of human embryos. http://investorshub.advfn.com/boards/read_msg.aspx?message_id=34779607
5. Patent Licenses "On December 31, 2003, Lifeline entered into an Option to License Intellectual Property agreement with Advanced Cell Technology, Inc. (“ACT”) for patent rights and paid ACT $340,000 in option and license fees. On February 13, 2004, Lifeline and ACT amended the Option agreement and Lifeline paid ACT additional option fees of $22,500 for fees related to registering ACT’s patents in selected international countries. http://investorshub.advfn.com/boards/read_msg.aspx?message_id=35261637
One of ACTC's licensee's OCEANSIDE, Calif., Jan 13, 2009 (BUSINESS WIRE) -- International Stem Cell Corporation (OTCBB: ISCO) has created layered human tissue from its unique parthenogenetic stem cells and transplanted this tissue into animals in pre-clinical trials to establish a potential new treatment for human retinal diseases, such as macular degeneration or retinitis pigmentosa. http://investorshub.advfn.com/boards/read_msg.aspx?message_id=36975910
PacGen to Lifeline to ISCO, The 3 licenses they received included a bunch. ACT License”, the “U Mass License” and the “Infigen License”,
From article, The 2005 licenses Lifeline Cell Technology entered into with ACT involved three exclusive license agreements for the production of therapeutic products in the fields of diabetes, liver disease, retinal disease, and the creation of research products in all fields
rumit, you are well aware of how the WARF license disappeared from last 10K because of non payment...well the UMASS license is currently stating the same language so I am not clear at all what we have and don't have..
UMass License - On February 1, 2002 and April 16, 1996, we entered into exclusive license agreements (indefinite license period) with the University of Massachusetts. The 1996 Agreement has been amended by amendments dated September 1, 1997, May 31, 2000 and September 19, 2002. Pursuant to these agreements, the University of Massachusetts, referred to as UMass, exclusively licensed to us certain biological materials, patent rights and related technology for commercialization in specified fields. The license agreements require us to use diligent efforts to develop licensed products and licensed services and require us to pay certain royalties, minimum annual royalties, milestone payments and sublicense income to UMass. UMass received 73,263 shares of common stock of ACT as partial consideration of the license granted. We are currently behind on our payments of all UMass license fees, since 2008, and as such we are in breach of the license agreement. http://www.sec.gov/Archives/edgar/data/1140098/000114420410013897/v177442_10k.htm
rumit, The Genomics Law Report was enlightening. It certainly raises questions as to the long term viability on Geron's WARF patents. I assume the ACTC patents will also expire in 2015. Is this correct? Thanks in advance.
News 
Market Data 
Discover 
